MannKind Corporation
General ticker "MNKD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B (TTM average)
MannKind Corporation does not follow the US Stock Market performance with the rate: -1.9%.
Estimated limits based on current volatility of 2.6%: low 3.90$, high 4.11$
Factors to consider:
- Total employees count: 592 (+45.5%) as of 2025
- Top business risk factors: Regulatory and compliance, Raw material shortages, Clinical trial failure, Capital access, Market volatility
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.64$, 6.97$]
- 2026-12-31 to 2027-12-31 estimated range: [3.86$, 7.31$]
Financial Metrics affecting the MNKD estimates:
- Positive: with PPE of 264.3 at the end of fiscal year the price was low
- Positive: 7.57 < Operating profit margin, % of 11.37
- Positive: -0.03 < Operating cash flow per share per price, % of 1.02
- Positive: -3.72 < Return on assets ratio (scaled to [-100,100]) of 0.73
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of -6.44 <= 19.19
Short-term MNKD quotes
Long-term MNKD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $197.05MM | $289.41MM | $341.22MM |
| Operating Expenses | $188.37MM | $216.82MM | $302.42MM |
| Operating Income | $8.68MM | $72.59MM | $38.80MM |
| Non-Operating Income | $-19.05MM | $-42.07MM | $-37.39MM |
| Interest Expense | $15.15MM | $11.98MM | $13.83MM |
| R&D Expense | $31.28MM | $45.89MM | $66.35MM |
| Income(Loss) | $-10.38MM | $30.52MM | $1.41MM |
| Taxes | $1.56MM | $2.93MM | $-4.46MM |
| Net Income(Loss)* | $-11.94MM | $27.59MM | $5.86MM |
| Stockholders Equity | $-246.17MM | $-78.82MM | $-51.02MM |
| Inventory | $28.55MM | $27.89MM | $35.31MM |
| Assets | $475.20MM | $393.84MM | $792.18MM |
| Operating Cash Flow | $34.09MM | $42.51MM | $18.25MM |
| Capital expenditure | $42.44MM | $9.69MM | $4.57MM |
| Investing Cash Flow | $-1.99MM | $-96.65MM | $-304.80MM |
| Financing Cash Flow | $136.61MM | $-137.27MM | $315.10MM |
| Earnings Per Share** | $-0.04 | $0.10 | $0.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.